Cancer stem cells: Are they responsible for treatment failure?

Future Oncology

Volumn 10, Issue 13, 2014, Pages 2033-2044

  Maugeri Saccà, Marcello ^a   Vici, Patrizia ^a   Di Lauro, Luigi ^a   Barba, Maddalena ^a   Amoreo, Carla Azzurra ^a   Gallo, Enzo ^a   Mottolese, Marcella ^a   De Maria, Ruggero ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptotic pathways; Cancer stem cells; Chemotherapy; Clonal evolution; CSC derived xenografts; Differentiation; Dna damage repair; Hierarchical model; Self renewal pathways; Survival pathways

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL RENEWAL; CELL SURVIVAL; CHEMORADIOTHERAPY; CLONAL EVOLUTION; DEMETHYLATION; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; HUMAN; MISMATCH REPAIR; NERVE CELL PLASTICITY; NONHUMAN; REVIEW; TREATMENT FAILURE; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS; RADIATION DOSE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84911164257     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/FON.14.126     Document Type: Review

References (97)

1. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138 (5), 822-829 (2009).
2. Illmensee K, Mintz B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl Acad. Sci. USA 73 (2), 549-553 (1976).
3. Fearon ER, Burke PJ, Schiffer CA, Zehnbauer BA, Vogelstein B. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N. Engl. J. Med. 315 (1), 15-24 (1986).
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (7), 730-737 (1997).
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100 (7), 3983-3988 (2003).
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (7123), 111-115 (2007).
7. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15 (3), 504-514 (2008).
8. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432 (7015), 396-401 (2004).
9. Todaro M, Iovino F, Eterno V. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 70 (21), 8874-8885 (2010).
10. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties inhead and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104 (3), 973-978 (2007).
11. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67 (3), 1030-1037 (2007).
12. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65 (23), 10946-10951 (2005).
13. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29 (18), 2672-2680 (2010).
14. Greaves M, Maley CC. Clonal evolution in cancer. Nature 481(7381), 306-313 (2012).
15. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (4), 663-676 (2006).
16. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (4), 704-715 (2008).
17. Vermeulen L, De Sousa E Melo F, van der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12 (5), 468-476 (2010).
18. Li Z, Bao S, Wu Q et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15 (5), 501-513 (2009).
19. Hjelmeland AB, Wu Q, Heddleston JM et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 18 (5), 829-840 (2011).
20. Todaro M, Gaggianesi M, Catalano V et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14(3), 342-356 (2014).
21. Pistollato F, Abbadi S, Rampazzo E et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28 (5), 851-862 (2010).
22. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66 (16), 7843-7848 (2006).
23. Wang R, Chadalavada K, Wilshire J et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468 (7325), 829-833 (2010).
24. Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468 (7325), 824-828 (2010).
25. Ricci-Vitiani L, Pallini R, Larocca LM. Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ. 15 (9), 1491-1498 (2008).
26. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 456 (7222), 593-598 (2008).
27. Pece S, Tosoni D, Confalonieri S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140 (1), 62-73 (2010).
28. Freitas DP, Teixeira CA, Santos-Silva F, Vasconcelos MH, Almeida GM. Therapyinduced enrichment of putative lung cancer stem-like cells. Int. J. Cancer 134(6), 1270-1278 (2014).
29. Dieter SM, Ball CR, Hoffmann CM et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9 (4), 357-365 (2011).
30. Piccirillo SG, Combi R, Cajola L et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28 (15), 1807-1811 (2009).
31. Anderson K, Lutz C, van Delft FW et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469 (7330), 356-361 (2011).
32. Notta F, Mullighan CG, Wang JC et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469 (7330), 362-367 (2011).
33. Maugeri-Saccà M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin. Cancer Res. 17 (15), 4942-4947 (2011).
34. Maugeri-Saccà M, Zeuner A, De Maria R. Therapeutic targeting of cancer stem cells. Front. Oncol. 1, 10 (2011)
35. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (7120), 756-760 (2006).
36. Bartucci M, Svensson S, Romania P et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 19(5), 768-778 ( 2012).
37. + tumor-initiating cell fraction. Stem Cells 29 (3), 418-429 (2011).
38. Goff DJ, Recart AC, Sadarangani A et al. A pan-BCL2 inhibitor renders bone-marrowresident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12(3), 316-328 (2013).
39. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1 (4), 389-402 (2007).
40. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26 (12), 3027-3036 (2008).
41. Sette G, Salvati V, Memeo L et al. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS ONE 7(10), e46891 (2012).
42. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17 (2), 165-172 (2007).
43. Eimer S, Dugay F, Airiau K et al. Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro Oncol. 14(12), 1441-1451 (2012).
44. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch- and Hedgehogdependent tumor-initiating cells. Cancer Cell 22(3), 373-388 (2012).
45. Lonardo E, Hermann PC, Mueller MT et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 9 (5), 433-446 (2011).
46. Bhola NE, Balko JM, Dugger TC et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123(3), 1348-1358 (2013).
47. Magnifico A, Albano L, Campaner S et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 15 (6), 2010-2021 (2009).
48. Fischer M, Yen WC, Kapoun AM et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 71(5), 1520-1525 (2011).
49. Ying M, Wang S, Sang Y et al. Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene 30 (31), 3454-3467 (2011).
50. Campos B, Wan F, Farhadi M et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin. Cancer Res. 16 (10), 2715-2728 (2010).
51. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumourinitiating cells. Nature 444 (7120), 761-765 (2006).
52. Tate CM, Pallini R, Ricci-Vitiani L et al. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ. 19(10), 1644-1654 (2012).
53. Persano L, Pistollato F, Rampazzo E et al. BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis. 3, e412 (2012).
54. Srikanth M, Kim J, Das S, Kessler JA. BMP signaling induces astrocytic differentiation of clinically derived oligodendroglioma propagating cells. Mol. Cancer Res. 12(2), 283-294 (2014).
55. Lombardo Y, Scopelliti A, Cammareri P et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140 (1), 297-309 (2011).
56. Kodach LL, Jacobs RJ, Voorneveld PW et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 60 (11), 1544-1553 (2011).
57. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 411 (6835), 366-374 (2001).
58. Maugeri-Saccà M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. Mol. Cancer Ther. 11(8), 1627-1636 (2012).
59. Maugeri-Saccà M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat. Rev. 39(5), 525-533 (2013).
60. Zhang M, Behbod F, Atkinson RL et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 68 (12), 4674-4682 (2008).
61. Maugeri-Saccà M, Di Martino S, De Maria R. Biological and clinical implications of cancer stem cells in primary brain tumors. Front. Oncol. 3, 6 (2013).
62. + cancer stem cells in glioblastoma. Mol. Cancer 5, 67 (2006).
63. Sciuscio D, Diserens AC, van Dommelen K et al. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin. Cancer Res. 17 (2), 255-266 (2011).
64. Signore M, Ricci-Vitiani L, De Maria R. Targeting apoptosis pathways in cancer stem cells. Cancer Lett. 332(2), 374-382 (2013).
65. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell 21 (1), 92-101 (2011).
66. Lang JY, Hsu JL, Meric-Bernstam F et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 20 (3), 341-356 (2011).
67. Todaro M, Lombardo Y, Francipane MG et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 15 (4), 762-772 (2008).
68. + breast cancer by expanding the cancer stem cell population. Mol. Cell 47(4), 570-584 (2012).
69. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10(3), 143-153 (2013).
70. Todaro M, Turdo A, Bartucci M et al. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res. 73(21), 6393-6400 (2013).
71. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373 (9674), 1532-1542 (2009).
72. Francescangeli F, Patrizii M, Signore M et al. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells 30 (9), 1819-1830 (2012).
73. Von Hoff DD, LoRusso PM, Rudin CM et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361 (12), 1164-1172 (2009).
74. Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361 (12), 1173-1178 (2009).
75. Kaye SB, Fehrenbacher L, Holloway R et al. A Phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin. Cancer Res. 18(23), 6509-6518 (2012).
76. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19(11), 1410-1422 (2013).
77. Schott AF, Landis MD, Dontu G et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin. Cancer Res. 19(6), 1512-1524 (2013).
78. Fan X, Khaki L, Zhu TS et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28 (1), 5-16 (2010).
79. Zhu TS, Costello MA, Talsma CE et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 71 (18), 6061-6072 (2011).
80. Yan M, Callahan CA, Beyer JC et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 463 (7282), E6-E7 (2010).
81. Krop I, Demuth T, Guthrie T et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30(19), 2307-2313 (2012).
82. Cordenonsi M, Zanconato F, Azzolin L et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 (4), 759-772 (2011).
83. Bartucci M, Dattilo R, Moriconi C et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene doi:10.1038/onc.2014.5 (2014) (Epub ahead of print).
84. Sanz MA, Montesinos P, Vellenga E et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood 112 (8), 3130-3134 (2008).
85. Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide and 13- cis -retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 21 (12), 2305-2311 (2003).
86. Butowski N, Prados MD, Lamborn KR et al. A Phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 61 (5), 1454-1459 (2005).
87. Lee J, Son MJ, Woolard K et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13 (1), 69-80 (2008).
88. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 33(36), 4451-4463 (2014).
89. Baiocchi M, Biffoni M, Ricci-Vitiani L, Pilozzi E, De Maria R. New models for cancer research: human cancer stem cell xenografts. Curr. Opin. Pharmacol. 10 (4), 380-384 (2010).
90. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356 (3), 217-226 (2007).
91. Gerger A, Zhang W, Yang D et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin. Cancer Res. 17 (21), 6934-6943 (2011).
92. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100 (9), 672-679 (2008).
93. Pallini R, Ricci-Vitiani L, Banna GL et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin. Cancer Res. 14 (24), 8205-8212 (2008).
94. Murat A, Migliavacca E, Gorlia T et al. Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26 (18), 3015-3024 (2008).
95. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11 (4), R46 (2009).
96. Raimondi C, Gradilone A, Naso G et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 130 (2), 449-455 (2011).
97. Nadal R, Ortega FG, Salido M et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int. J. Cancer 133(10), 2398-2407 (2013).